Market Overview

7 Biggest Price Target Changes For Tuesday

Share:
Related PTXP
Benzinga's Top Upgrades, Downgrades For May 22, 2017
Analyst Expects Energy Transfer's Deal To Acquire PennTex Will Close
Related BMRN
BioMarin (BMRN) Down 8% Since Earnings Report: Can It Rebound?
Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates
The Vetr community has upgraded $BMRN to 3.5-Stars. (Vetr)

 

  • Barclays cut BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) price target from $125 to $105. BioMarin Pharmaceutical shares closed at $88.36 on Monday.
  • SunTrust Robinson Humphrey lowered the price target on Penntex Midstream Partners LP (NASDAQ: PTXP) from $20 to $18. Penntex Midstream Partners shares closed at $16.69 on Monday.
  • Imperial Capital lowered the price target for Palo Alto Networks Inc (NYSE: PANW) from $190 to $180. Palo Alto Networks shares closed at $136.26 on Monday.
  • Barclays cut the price target on United Therapeutics Corporation (NASDAQ: UTHR) from $115 to $100. United Therapeutics shares closed at $132.74 on Monday.
  • Baird cut the price target for Nivalis Therapeutics Inc (NASDAQ: NVLS) from $29 to $3. Nivalis Therapeutics shares closed at $6.25 on Monday.
  • Leerink Partners lowered the price target for Amicus Therapeutics, Inc. (NASDAQ: FOLD) from $17 to $15. Amicus Therapeutics shares closed at $8.32 on Monday.
  • Barclays cut the price target for Johnson & Johnson (NYSE: JNJ) from $130 to $125. Johnson & Johnson shares closed at $113.13 on Monday.

Latest Ratings for PTXP

DateFirmActionFromTo
May 2017CitigroupDowngradesBuyNeutral
May 2017BairdDowngradesOutperformNeutral
May 2017RBC CapitalDowngradesOutperformSector Perform

View More Analyst Ratings for PTXP
View the Latest Analyst Ratings

Posted-In: Price Target ChangesPrice Target Analyst Ratings

 

Related Articles (BMRN + FOLD)

View Comments and Join the Discussion!